Possible molecular targets of novel ruthenium complexes in antiplatelet therapy

Thanasekaran Jayakumar, Chia Yuan Hsu, Themmila Khamrang, Chih Hsuan Hsia, Chih Wei Hsia, Manjunath Manubolu, Joen Rong Sheu

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

In oncotherapy, ruthenium (Ru) complexes are reflected as potential alternatives for platinum compounds and have been proved as encouraging anticancer drugs with high efficacy and low side effects. Cardiovascular diseases (CVDs) are mutually considered as the number one killer globally, and thrombosis is liable for the majority of CVD-related deaths. Platelets, an anuclear and small circulating blood cell, play key roles in hemostasis by inhibiting unnecessary blood loss of vascular damage by making blood clot. Platelet activation also plays a role in cancer metastasis and progression. Nevertheless, abnormal activation of platelets results in thrombosis under pathological settings such as the rupture of atherosclerotic plaques. Thrombosis diminishes the blood supply to the heart and brain resulting in heart attacks and strokes, respectively. While currently used anti-platelet drugs such as aspirin and clopidogrel demonstrate efficacy in many patients, they exert undesirable side effects. Therefore, the development of effective therapeutic strategies for the prevention and treatment of thrombotic diseases is a demanding priority. Recently, precious metal drugs have conquered the subject of metal-based drugs, and several investigators have motivated their attention on the synthesis of various ruthenium (Ru) complexes due to their prospective therapeutic values. Similarly, our recent studies established that novel ruthenium-based compounds suppressed platelet aggregation via inhibiting several signaling cascades. Our study also described the structure antiplatelet-activity relationship (SAR) of three newly synthesized ruthenium-based compounds. This review summarizes the antiplatelet activity of newly synthesized ruthenium-based compounds with their potential molecular mechanisms.

Original languageEnglish
Article number1818
JournalInternational Journal of Molecular Sciences
Volume19
Issue number6
DOIs
Publication statusPublished - Jun 20 2018

Fingerprint

Ruthenium Compounds
Ruthenium
Platelets
platelets
ruthenium
therapy
thrombosis
Thrombosis
drugs
Blood
clopidogrel
Platelet Activation
blood
Pharmaceutical Preparations
Cardiovascular Diseases
Blood Platelets
Metals
Platinum Compounds
Platinum compounds
Chemical activation

Keywords

  • Antiplatelet
  • Antithrombosis
  • Ruthenium complex
  • Signaling cascades

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Possible molecular targets of novel ruthenium complexes in antiplatelet therapy. / Jayakumar, Thanasekaran; Hsu, Chia Yuan; Khamrang, Themmila; Hsia, Chih Hsuan; Hsia, Chih Wei; Manubolu, Manjunath; Sheu, Joen Rong.

In: International Journal of Molecular Sciences, Vol. 19, No. 6, 1818, 20.06.2018.

Research output: Contribution to journalReview article

Jayakumar, Thanasekaran ; Hsu, Chia Yuan ; Khamrang, Themmila ; Hsia, Chih Hsuan ; Hsia, Chih Wei ; Manubolu, Manjunath ; Sheu, Joen Rong. / Possible molecular targets of novel ruthenium complexes in antiplatelet therapy. In: International Journal of Molecular Sciences. 2018 ; Vol. 19, No. 6.
@article{b1d4ddc63af14436bd5a11f721f3a518,
title = "Possible molecular targets of novel ruthenium complexes in antiplatelet therapy",
abstract = "In oncotherapy, ruthenium (Ru) complexes are reflected as potential alternatives for platinum compounds and have been proved as encouraging anticancer drugs with high efficacy and low side effects. Cardiovascular diseases (CVDs) are mutually considered as the number one killer globally, and thrombosis is liable for the majority of CVD-related deaths. Platelets, an anuclear and small circulating blood cell, play key roles in hemostasis by inhibiting unnecessary blood loss of vascular damage by making blood clot. Platelet activation also plays a role in cancer metastasis and progression. Nevertheless, abnormal activation of platelets results in thrombosis under pathological settings such as the rupture of atherosclerotic plaques. Thrombosis diminishes the blood supply to the heart and brain resulting in heart attacks and strokes, respectively. While currently used anti-platelet drugs such as aspirin and clopidogrel demonstrate efficacy in many patients, they exert undesirable side effects. Therefore, the development of effective therapeutic strategies for the prevention and treatment of thrombotic diseases is a demanding priority. Recently, precious metal drugs have conquered the subject of metal-based drugs, and several investigators have motivated their attention on the synthesis of various ruthenium (Ru) complexes due to their prospective therapeutic values. Similarly, our recent studies established that novel ruthenium-based compounds suppressed platelet aggregation via inhibiting several signaling cascades. Our study also described the structure antiplatelet-activity relationship (SAR) of three newly synthesized ruthenium-based compounds. This review summarizes the antiplatelet activity of newly synthesized ruthenium-based compounds with their potential molecular mechanisms.",
keywords = "Antiplatelet, Antithrombosis, Ruthenium complex, Signaling cascades",
author = "Thanasekaran Jayakumar and Hsu, {Chia Yuan} and Themmila Khamrang and Hsia, {Chih Hsuan} and Hsia, {Chih Wei} and Manjunath Manubolu and Sheu, {Joen Rong}",
year = "2018",
month = "6",
day = "20",
doi = "10.3390/ijms19061818",
language = "English",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "6",

}

TY - JOUR

T1 - Possible molecular targets of novel ruthenium complexes in antiplatelet therapy

AU - Jayakumar, Thanasekaran

AU - Hsu, Chia Yuan

AU - Khamrang, Themmila

AU - Hsia, Chih Hsuan

AU - Hsia, Chih Wei

AU - Manubolu, Manjunath

AU - Sheu, Joen Rong

PY - 2018/6/20

Y1 - 2018/6/20

N2 - In oncotherapy, ruthenium (Ru) complexes are reflected as potential alternatives for platinum compounds and have been proved as encouraging anticancer drugs with high efficacy and low side effects. Cardiovascular diseases (CVDs) are mutually considered as the number one killer globally, and thrombosis is liable for the majority of CVD-related deaths. Platelets, an anuclear and small circulating blood cell, play key roles in hemostasis by inhibiting unnecessary blood loss of vascular damage by making blood clot. Platelet activation also plays a role in cancer metastasis and progression. Nevertheless, abnormal activation of platelets results in thrombosis under pathological settings such as the rupture of atherosclerotic plaques. Thrombosis diminishes the blood supply to the heart and brain resulting in heart attacks and strokes, respectively. While currently used anti-platelet drugs such as aspirin and clopidogrel demonstrate efficacy in many patients, they exert undesirable side effects. Therefore, the development of effective therapeutic strategies for the prevention and treatment of thrombotic diseases is a demanding priority. Recently, precious metal drugs have conquered the subject of metal-based drugs, and several investigators have motivated their attention on the synthesis of various ruthenium (Ru) complexes due to their prospective therapeutic values. Similarly, our recent studies established that novel ruthenium-based compounds suppressed platelet aggregation via inhibiting several signaling cascades. Our study also described the structure antiplatelet-activity relationship (SAR) of three newly synthesized ruthenium-based compounds. This review summarizes the antiplatelet activity of newly synthesized ruthenium-based compounds with their potential molecular mechanisms.

AB - In oncotherapy, ruthenium (Ru) complexes are reflected as potential alternatives for platinum compounds and have been proved as encouraging anticancer drugs with high efficacy and low side effects. Cardiovascular diseases (CVDs) are mutually considered as the number one killer globally, and thrombosis is liable for the majority of CVD-related deaths. Platelets, an anuclear and small circulating blood cell, play key roles in hemostasis by inhibiting unnecessary blood loss of vascular damage by making blood clot. Platelet activation also plays a role in cancer metastasis and progression. Nevertheless, abnormal activation of platelets results in thrombosis under pathological settings such as the rupture of atherosclerotic plaques. Thrombosis diminishes the blood supply to the heart and brain resulting in heart attacks and strokes, respectively. While currently used anti-platelet drugs such as aspirin and clopidogrel demonstrate efficacy in many patients, they exert undesirable side effects. Therefore, the development of effective therapeutic strategies for the prevention and treatment of thrombotic diseases is a demanding priority. Recently, precious metal drugs have conquered the subject of metal-based drugs, and several investigators have motivated their attention on the synthesis of various ruthenium (Ru) complexes due to their prospective therapeutic values. Similarly, our recent studies established that novel ruthenium-based compounds suppressed platelet aggregation via inhibiting several signaling cascades. Our study also described the structure antiplatelet-activity relationship (SAR) of three newly synthesized ruthenium-based compounds. This review summarizes the antiplatelet activity of newly synthesized ruthenium-based compounds with their potential molecular mechanisms.

KW - Antiplatelet

KW - Antithrombosis

KW - Ruthenium complex

KW - Signaling cascades

UR - http://www.scopus.com/inward/record.url?scp=85048932285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048932285&partnerID=8YFLogxK

U2 - 10.3390/ijms19061818

DO - 10.3390/ijms19061818

M3 - Review article

AN - SCOPUS:85048932285

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 6

M1 - 1818

ER -